Recent Advances in Basic Research for CSF1R-Microglial Encephalopathy.

Area of Science:

• Neuroscience
• Genetics
• Immunology

Background:

• Colony-stimulating factor-1 receptor (CSF1R) mutations cause rare, rapidly progressive dementias like pigmentary orthochromatic leukodystrophy (POLD), hereditary diffuse leukoencephalopathy with spheroids (HDLS), and adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).
• CSF1R is crucial for microglial function and number; mutations disrupt these processes, leading to neurodegeneration.
• Current treatments are limited, highlighting the need for novel therapeutic approaches.

Purpose of the Study:

• To review CSF1R mutations, their pathogenetic mechanisms, and associated neurological disorders.
• To summarize existing animal models used to study CSF1R-related encephalopathies.
• To evaluate the feasibility of microglial replacement therapy as a potential treatment strategy.

Main Methods:

• Literature review of studies on CSF1R mutations and related leukoencephalopathies.
• Analysis of various animal models (zebrafish, mice, rats) with different CSF1R genetic alterations.
• Examination of research on microglial function and immunotherapy.

Main Results:

• Identified key CSF1R mutation sites and elucidated their pathogenic mechanisms.
• Detailed the utility of diverse animal models in understanding disease progression.
• Highlighted microglial replacement therapy as a promising, albeit challenging, therapeutic avenue.

Conclusions:

• CSF1R mutations lead to distinct leukoencephalopathies through impaired microglial function.
• Animal models are essential tools for dissecting disease mechanisms and testing interventions.
• Microglia-original immunotherapy presents a novel therapeutic frontier for CSF1R-related encephalopathies.